Bibliographic information
GuidelineWHO guidelines on tuberculosis infection prevention and control: 2019 update
Year of Publication2019
Issuing InstitutionWHO
Recommendation
Maintained
Originally developed
Bedaquiline should be included in longer multidrug-resistant TB (MDR-TB) regimens for patients aged 18 years or more. Bedaquiline may also be included in longer multidrug-resistant tuberculosis (MDR-TB) regimens for patients aged 6–17 years
Recommended in favor
Strong
Certainty of evidence
Moderate
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents.
Year2022
InstitutionWHO